We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+8.12%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$2.82B
AUM Growth
+$110M
Cap. Flow
-$28.2M
Cap. Flow %
-1%
Top 10 Hldgs %
24.59%
Holding
328
New
19
Increased
84
Reduced
138
Closed
16

Sector Composition

Rank Sector Weight
1 Technology 29.95%
2 Healthcare 22.66%
3 Industrials 15.17%
4 Consumer Discretionary 14.57%
5 Communication Services 5.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FATE icon
51
Fate Therapeutics
FATE
$326M
$14.6M 0.52%
250,212
-10,544
-4% -$598K
ASND icon
52
Ascendis Pharma A/S
ASND
$16.8B
$13.4M 0.48%
99,861
+23,095
+30% +$3.44M
COLL icon
53
Collegium Pharmaceutical
COLL
$956M
$13.2M 0.47%
704,201
-48,837
-6% -$952K
LMAT icon
54
LeMaitre Vascular
LMAT
$1.86B
$12.8M 0.45%
255,092
+2,823
+1% +$146K
ZGNX
55
DELISTED
Zogenix, Inc.
ZGNX
$12.6M 0.45%
774,926
-48,357
-6% -$708K
IOVA icon
56
Iovance Biotherapeutics
IOVA
$2.87B
$12.1M 0.43%
631,784
-230,163
-27% -$5.07M
GDDY icon
57
GoDaddy
GDDY
$11.5B
$12M 0.43%
+141,519
New +$10.1M
TFX icon
58
Teleflex
TFX
$5.98B
$11.5M 0.41%
35,045
-4,057
-10% -$1.38M
UTMD icon
59
Utah Medical Products
UTMD
$225M
$11.4M 0.4%
113,833
-952
-0.8% -$97.1K
ARNA
60
DELISTED
Arena Pharmaceuticals Inc
ARNA
$11.1M 0.39%
119,426
-125,969
-51% -$8.3M
GBT
61
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11M 0.39%
375,518
-34,263
-8% -$1.06M
AAP icon
62
Advance Auto Parts
AAP
$3.49B
$10.9M 0.39%
45,614
-4,815
-10% -$1.1M
ACAD icon
63
Acadia Pharmaceuticals
ACAD
$5.03B
$10.8M 0.38%
461,051
-35,706
-7% -$718K
ACLS icon
64
Axcelis
ACLS
$4.33B
$10.7M 0.38%
143,449
+19,824
+16% +$1.17M
ALBO
65
DELISTED
Albireo Pharma Inc
ALBO
$10.7M 0.38%
458,011
-49,670
-10% -$1.32M
PCOM
66
DELISTED
Points.com Inc. Common Shares
PCOM
$10.6M 0.38%
695,361
-140,761
-17% -$2.39M
ATEN icon
67
A10 Networks
ATEN
$1.95B
$10.2M 0.36%
614,640
+113,414
+23% +$1.72M
CMBM
68
DELISTED
Cambium Networks
CMBM
$10.2M 0.36%
397,154
+356,784
+884% +$10.3M
CCSI icon
69
Consensus Cloud Solutions
CCSI
$647M
$9.87M 0.35%
+170,468
New +$10.4M
ITRN icon
70
Ituran Location and Control
ITRN
$1.05B
$9.01M 0.32%
337,976
-33,267
-9% -$873K
AERI
71
DELISTED
Aerie Pharmaceuticals
AERI
$8.45M 0.3%
1,203,592
-29,008
-2% -$304K
KNSA icon
72
Kiniksa Pharmaceuticals
KNSA
$5.93B
$8.39M 0.3%
712,807
-24,567
-3% -$302K
KPTI icon
73
Karyopharm Therapeutics
KPTI
$48M
$8.21M 0.29%
85,109
-8,348
-9% -$832K
CSW
74
CSW Industrials
CSW
$5.71B
$8.18M 0.29%
67,674
-9,929
-13% -$1.29M
ICLR icon
75
Icon
ICLR
$12.7B
$8.15M 0.29%
26,303
-1,845
-7% -$516K

Similar funds

Rice Hall James & Associates's Q4 2021 Portfolio in Review

As of Q4 2021, Rice Hall James & Associates held 328 positions worth $2.82B, up 4.1% from $2.71B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rice Hall James & Associates's Q4 2021 filing shows 19 new, 84 increased, 138 reduced and 16 closed positions. Its largest new stake was Consensus Cloud Solutions: 170,468 shares worth $9.87M. The largest sale was Echo Global Logistics, Inc., an estimated $31.9M.

By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 26% a quarter earlier, followed by Healthcare and Industrials.

  • Rice Hall James & Associates's largest Q4 2021 buy was Consensus Cloud Solutions: 170,468 shares worth $9.87M.
  • Rice Hall James & Associates added most to Euronet Worldwide in Q4 2021, an estimated $20.2M increase.
  • Rice Hall James & Associates's biggest Q4 2021 reduction was Ziff Davis, cutting an estimated $15.2M.
  • Rice Hall James & Associates fully exited Echo Global Logistics, Inc. in Q4 2021, selling an estimated $31.9M.
  • Rice Hall James & Associates's ten largest holdings make up 25% of its $2.82B portfolio in Q4 2021.
  • Rice Hall James & Associates opened 19 new positions and closed 16 in Q4 2021.
  • Rice Hall James & Associates's portfolio value rose 4.1% quarter-over-quarter to $2.82B.

Based on Rice Hall James & Associates's 13F filing for Q4 2021, filed 14 Feb 2022.